CAMBRIDGE, Massachusetts, May 8, 2026, 15:07 EDT
Shares of Moderna Inc. shot up Friday, gaining about 10% to $53.41, after the company announced work on vaccines targeting hantaviruses—a rare focus for drugmakers that’s suddenly drawing attention as a fatal outbreak linked to the MV Hondius cruise ship unfolds. Moderna earlier hit a session high of $57.77.
This comes at a pivotal moment for Moderna. Investors want to see real results from the company’s mRNA platform — the tech behind its COVID-19 shot — and whether it can push out fresh products beyond the pandemic-era blockbuster. A cruise ship outbreak has suddenly put an early research project in the spotlight as a potential market mover.
The World Health Organization has tallied eight reported cases so far, with three fatalities. Five of those are confirmed hantavirus infections. The culprit: Andes virus. According to WHO, it’s the only hantavirus species capable of limited person-to-person spread, typically after extended close contact.
This isn’t about Moderna rolling out a product anytime soon. According to Seeking Alpha, the biotech is just getting started on a hantavirus vaccine—it’s early days, and any launch is likely still years off. Yet the stock surged Friday afternoon.
Moderna’s hantavirus efforts, at least the ones on the record, feature a deal with Korea University’s Vaccine Innovation Center—inked prior to the present outbreak. As part of that collaboration, the Korean side shared hantavirus antigen sequence data, and Moderna sent over mRNA substances to support initial research into a more wide-ranging vaccine.
Francesca Ceddia, chief medical officer at Moderna, said in Korea University’s statement the collaboration should “strengthen mRNA vaccine research and development capabilities in Korea.” Heejin Cheong, who leads the Vaccine Innovation Center, said both groups plan to continue efforts on an mRNA-based hantavirus vaccine. EurekAlert!
Public health officials are urging investors not to overreact. WHO Director-General Tedros Adhanom Ghebreyesus described the situation as serious, but maintained that the agency sees “the public health risk as low.” Still, he cautioned that additional cases remain possible, given the virus’s incubation period. World Health Organization
“It’s not the next pandemic,” Michael Osterholm, head of the University of Minnesota’s Center for Infectious Diseases Research and Policy, told STAT. He added that proper respiratory protection should be enough to curb transmission now. STAT
Even so, the outbreak triggered a swift response from governments abroad. The U.S. State Department is organizing a repatriation flight for 17 Americans from the Dutch cruise ship, soon set to dock in Tenerife, Spain.
Moderna shares are also getting a lift from encouraging developments elsewhere in its vaccine pipeline. Reuters said this week the company’s experimental seasonal flu shot beat a standard-dose flu vaccine from GSK in a late-stage trial involving over 40,000 adults aged 50 and up. The FDA’s decision on that shot is due by Aug. 5.
Still, investors face the possibility that Friday’s action could be outpacing both the underlying science and the scope of the market. Evercore ISI analysts, cited by Barron’s, flagged that there’s little revenue likely from the outbreak—hantavirus cases are uncommon, and Moderna’s vaccine project is just getting off the ground.
For Moderna, the key issue right now isn’t whether hantavirus grows into a major revenue driver. What’s at stake is whether every new infectious disease in the headlines prompts investors to rethink a company still dealing with the aftermath of its COVID-era surge. “Near-term, things appear to have stabilized,” Bernstein analyst Courtney Breen told Reuters after Moderna’s first-quarter results, adding that focus is moving toward non-COVID opportunities. Reuters
